Market Size

The global molecular diagnostics market, valued at USD 17 billion in 2025, is projected to reach USD 18 billion in 2026 and USD 31 billion by 2035, with a 6.4% CAGR during the forecast period 2026 to 2035.

See What’s in the Full Report – Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size & Trends

In terms of test type, the laboratory testing segment holds the highest share (85%) of the market.
With regards to type of offering, the reagents segment dominates the global market with 70% market share.
Based on the type of sample, the blood, serum and plasma reagents hold the largest market share (nearly 90%) in 2026.
In terms of type of technology, the PCR segment dominates the global market with more than 40% market share.
With respect to therapeutic area, infectious diseases segment captures the highest share in 2026.
With regards to end users, the hospitals segment dominates the global market.
In terms of geographical regions, North America captures the majority of the market share, and Asia-Pacific is likely to grow at a faster pace in the near future.

Key Market Statistics

Market Size in 2026: $18 Billion
Estimated Market Size in 2035: $31 Billion
CAGR (2026-2035): 6.4%
North America: Largest market in 2026
Asia-Pacific: Fastest growing region

Market Overview

Molecular diagnostic tests refer to tests designed to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease. Further, such tests also aim to identify single nucleotide polymorphisms, deletions, rearrangements, and insertions in the genetic sequences. It is worth mentioning that molecular diagnostics is a subset of the in vitro diagnostics market.

According to the World Health Organization, over 40,000 in vitro diagnostics products are currently available in the market. This vast array of products highlights the critical role of diagnostics in healthcare. It is worth mentioning that over 70% of the healthcare decisions are made based on laboratory test results, as they provide essential data that informs diagnoses, guide treatment choices, monitor disease progression and assess responses to therapy. This underscores the indispensable role of laboratory professionals and diagnostic testing in ensuring accurate, timely and effective patient care.

Molecular diagnostic tests play a crucial role in diagnosing various diseases, monitoring healthcare responses, and predicting healthcare outcomes. Given the benefits offered by such diagnostic solutions to provide rapid diagnostic results and improve patient outcomes, the global market is likely to grow at a healthy CAGR during the forecast period. This molecular diagnostics market growth is due to several factors, including the growing demand for point of care diagnostics devices, rapid diagnostics testing, and the increasing prevalence of infectious diseases.

In conclusion, the molecular diagnostics industry is likely to demonstrate robust growth, driven by technological advancements, increasing prevalence of infectious and chronic diseases, and a growing emphasis on personalized medicine. As innovations in genomics and point-of-care testing continue to emerge, the market is likely to witness expanded applications and improved accessibility, worldwide. Ultimately, molecular diagnostics will play an increasingly vital role in transforming disease detection, patient management and overall healthcare outcomes in the years ahead.

Recent Developments in Molecular Diagnostics Market

In March 2026, Insight Molecular Diagnostics completed key milestones for GraftAssureDx test, including a three-site reproducibility study at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health.
In March 2026, Ontario government provided $1.1 million funding through NOHFC to RNA Diagnostics in Sudbury for VeriDART cancer diagnostic technology research.
In September 2025, Illumina collaborated with multiple global pharmaceutical companies to develop companion diagnostics for KRAS alterations using TruSight Oncology comprehensive genomic profiling test, advancing personalized cancer care by targeting uncontrolled cell growth leading to cancer.

Pay Only for What You Need – The Best Way to Optimize

Molecular Diagnostics Market Trends

Rising Key Development Efforts Amongst the Industry Stakeholders to Foster Progress and Innovation in Expanding their Capabilities: Stakeholders in this domain have entered into numerous partnerships and collaborations, allowing them to expand their respective offerings and enhance their capabilities and visibility. Notably, in the last few years, companies across various geographies have inked multiple partnerships to strengthen their molecular diagnostics capabilities.

In June 2025, Tracer Biotechnologies announced a strategic partnership with QIAGEN to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN’s QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples.

Technological Advancements to Fuel Innovation and Drive Efficiency: Recent technological advancements in molecular diagnostics are transforming disease detection and patient care by enabling faster, more accurate and more personalized testing. A range of novel molecular diagnostic tests are also being developed for rapid, sensitive and specific molecular detection for diagnosing, treating and prognosing cancer patients.

Additionally, recent advances in molecular allergology have transformed allergy diagnostics through innovative approaches in allergen characterization, including allergen structure and biomarker identification. Component-resolved diagnosis (CRD) has reduced misdiagnosis rates by 40% in pollen-food syndrome cases, by distinguishing primary sensitizations from cross-reactivity. These advances in molecular diagnostics support allergen immunotherapy (AIT) decisions, particularly for complex polysensitizations, and facilitate the development of new forms of immunotherapy.

Market Share by Type of Sample: Blood, Serum and Plasma Segment to Hold the Highest Market Share

This segment highlights the distribution of market for molecular diagnostics across various types of samples, such as blood, serum and plasma, urine and others.
In 2026, blood, serum and plasma segments are likely to capture more than 75% of the overall market share, owing to its widespread use in detecting infectious diseases, cancer biomarkers and genetic conditions.
It is worth highlighting that the market for urine segment is likely to grow at a relatively higher CAGR (7.0%), during the forecast period. This is a result of recent attraction towards urine sampling, particularly in detecting urological cancers and infectious diseases, due to their non-invasive nature.

Molecular Diagnostics Market by Sample Type, 2026

Market Share by Test Type: Laboratory Testing Segment Holds the Largest Market Share

This segment highlights the distribution of market value for molecular diagnostics across laboratory testing and point-of-care testing.
In 2026, the laboratory testing segment occupies the higher market share (85%) and this trend is unlikely to change in the future.
It is worth mentioning that the point-of-care testing segment is likely to grow at a relatively higher (9.1%), during the forecast period, owing to their ability to deliver rapid test results and offer improved accessibility.

Market Share by Type of Offering: Reagents Segment to Dominate the Overall Market

This segment highlights the distribution of global molecular diagnostics market across various types of offerings such as reagents, instruments and services.
Among these types of offerings, the reagents segment occupies the highest market share (70%) in 2026. This is due to the fact that reagents are required to be replenished frequently, generating a continuous flow of revenue.
Further, the market for instruments segment is likely to grow at a relatively higher CAGR (6.6%), during the forecast period due to their recurring demand and technological advancements for efficient and accurate diagnostic procedures.

Molecular Diagnostics Market by Company Competitiveness Analysis

Market Share by Type of Technology: Next Generation Sequencing Segment to Grow at a Higher CAGR

Based on the type of technology, the overall market includes polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology, next generation DNA sequencing, microarrays, mass spectrometry and other types of technologies.
In 2026, polymerase chain reaction (PCR) segment captures more than 40% of the overall market share, owing to its accuracy, speed, and widespread application in diagnosing infectious diseases, genetic disorders, and cancer.
However, the next generation sequencing segment is likely to grow at a higher CAGR of 7.3% during the forecast period, which is most likely to be driven by its ability to provide comprehensive genomic information and advance personalized medicine.

Molecular Diagnostics Market by Technology Type, 2026

Market Share by Therapeutic Area: Infectious Diseases Segment to Dominate the Overall Market

Based on the therapeutic area, the overall market includes infectious diseases, oncological disorders, cardiovascular diseases, neurological diseases, genetic diseases and other disorders.
According to our molecular diagnostics market report, in 2026, infectious diseases segment captures more than 40% of the overall market share, owing to the increasing prevalence of various respiratory infections, such as influenza, respiratory syncytial virus (RSV), and pneumonia.
Further, the neurological diseases segment is likely to grow at a higher CAGR of 6.9% during the forecast period, owing to the advancements in understanding the genetic and molecular basis of neurological conditions, leading to more accurate and early diagnoses, personalized treatment plans and the identification of potential therapeutic targets.

Market Share by End User: Laboratories Segment to Grow at a Higher CAGR

Based on the end user, the overall market includes hospitals, laboratories and other end user.
In 2026, hospitals segment captures around 50% of the overall market share and is likely to grow at a relatively higher CAGR, during the forecast period.
This is due to the fact that a high volume of diagnostic tests are performed in-house for patient management and immediate diagnostic results for critical conditions within the hospital-settings.

Molecular Diagnostics Market by Porter's Five Forces Analysis

Market Share by Geographical Regions: Asia to Propel in the Molecular Diagnostics Sector in the Coming Years

This segment highlights the distribution of global market across various geographical regions, such as North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the World.
According to our projections, North America is likely to capture the majority (~40%) of the molecular diagnostics market share in 2026, and this trend is unlikely to change in the future.
It is worth highlighting that the market in Asia is likely to grow at a relatively higher CAGR (6.5%), during the forecast period. This is a result of the increasing prevalence of both infectious and chronic diseases, a rapidly aging population and significant technological advancements in diagnostic methods.

Want Information on Specific Region / Segment?

Key Market Insights

Molecular Diagnostics Companies Competitive Landscape

The current market landscape features more than 100 companies including very large, large, mid-sized and small companies. These companies have the required expertise to develop and provide molecular diagnostic solutions, across different geographical regions.

Notably, North America features the presence of 55% of the molecular diagnostic solutions providers, followed by Europe (30%). In addition to this, close to 90% of the companies offer next generation sequencing technologies, followed by microarrays (85%) and mass spectrometry (80%).

Market Size Analysis: Global Market to Grow at High CAGR

The global molecular diagnostics market size is likely to be worth USD 18 billion in 2026 and will reach USD 31 billion by 2035. In terms of the sample type, the global market is categorized into blood, serum and plasma, urine and others. In 2026, the blood, serum and plasma segment dominates the market and holds 80% of the market share, owing to its widespread use in detecting infectious diseases, cancer biomarkers and genetic conditions.

Further, the market size for urine samples segment is likely to grow at a relatively higher CAGR of 7.0 % during the forecast period. The improved sensitivity, faster turnaround times and non-invasiveness are the primary drivers of this market segment. Additionally, owing to the growing interest in personalized healthcare and rising prevalence of chronic and infectious diseases around the globe, we believe that the global molecular diagnostics industry is likely to grow at a steady rate during the forecast period.

Have Questions? Let’s Get Them Answered.

Regional Analysis: Which Region Holds the Largest Molecular Diagnostics Market Share?

North America is Leading the Market

North American companies will likely dominate the global molecular diagnostics market in 2035, owing to the robust research and development activities, coupled with increasing demand for molecular diagnostics and personalized medicines.

Asia-Pacific: An Emerging Growth Spot

The market in Asia-Pacific is likely to grow at a relatively high CAGR (6.5%), during the forecast period till 2035. This is a result of increased healthcare spending and government initiatives to improve healthcare infrastructure, alongside a surge in demand for personalized medicine and companion diagnostics development, in this region.

Market Drivers: Growing Shift Towards Personalized Healthcare and Increasing Prevalence of Chronic Diseases

The growing interest in personalized healthcare is a significant driver of the molecular diagnostics market. Molecular diagnostics play a crucial role in this paradigm by providing genetic and molecular insights that enable tailored treatment approaches. Further, advanced molecular diagnostic technologies, such as PCR and next-generation sequencing, are at the forefront of this transformation as these technologies facilitate comprehensive genetic analysis and enable the identification of mutations associated with various diseases.
It is worth mentioning that the application of molecular diagnostics for chronic diseases in facilitating early detection and personalized treatment is becoming increasingly vital. This evolution not only enhances patient care but also supports public health initiatives aimed at controlling and preventing disease outbreaks.

Market Challenges: Data Security Concerns May Hinder the Growth

Despite their several benefits, the use of molecular diagnostics presents several challenges. One of the most significant issues is the shortage of skilled workforce. Further, the integration of external data sources, such as patient health records, genomic data and real-world healthcare results requires advanced data management infrastructure and cybersecurity measures in order to protect patient’s privacy and ensure data security and compliance.

Market Segmentation Insights

Key Report Attributes	Details
Historical Trend	Since 2018
Forecast Period	Till 2035
Market Size 2026	$ 18 Billion
Market Size 2035	$ 31 Billion
CAGR (Till 2035)	6.4%
Test Type	Laboratory Testing Point-of-Care Testing
Type of Offering	Reagents Instruments Services
Type of Sample	Blood, Serum and Plasma Urine Others
Type of Technology	Polymerase Chain Reaction (PCR) In situ Hybridization Isothermal Nucleic Acid Amplification Technology Next Generation Sequencing Microarrays Mass Spectrometry Others
Therapeutic Area	Cardiovascular Diseases Genetic Diseases Infectious Diseases Neurological Diseases Oncological Disorders Others
End User	Hospitals Laboratories Others
Geographical Regions	North America US Canada Europe Austria Belgium Germany France UK Italy Spain Netherlands Poland Switzerland Rest of the Europe Asia China Japan India Indonesia South Korea Singapore Thailand Rest of Asia Latin America Brazil Argentina Mexico Rest of Latin America Middle East and North Africa Egypt Israel Saudi Arabia Rest of Middle East and North Africa Rest of the World Australia New Zealand
Excel Data Packs (Complimentary)	Market Landscape Company Competitiveness Analysis Market Forecast and Opportunity Analysis
Key Players	Abbott Laboratories Agilent Technologies Becton Dickinson BGI Genomics bioMerieux Bio-Rad Danaher DiaSorin Grifols Hologic Illumina Qiagen QuidelOrtho Revvity Roche Sansure Seegene Siemens Healthineers Sysmex Thermo Fisher Scientific A complete list of more than 100 companies is available in the report
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Table of Content

+ 1. BACKGROUND

1.1. Context

1.2. Project Objectives

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.3. Project Methodology

2.4. Forecast Methodology

2.5. Robust Quality Control

2.6. Key Market Segmentations

2.7. Key Factors

2.7.1. Demographics

2.7.2. Economic Factors

2.7.3. Government Regulations

2.7.4. Supply Chain

2.7.5. COVID Impact

2.7.6. Market Access

2.7.7. Healthcare Policies

2.7.8. Industry Consolidation

+ 3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview

3.2. Market Dynamics

3.2.1. Time Period

3.2.1.1. Historical Trends

3.2.1.2. Current and Future

3.2.2. Currency Coverage and Foreign Exchange Rate

3.2.2.1. Major Currencies Affecting the Market

3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates

3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market

3.2.2.4. Strategies for Mitigating Foreign Exchange Risk

3.2.3. Trade Policies

3.2.3.1. Impact of Trade Barriers on the Market

3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers

3.2.4. Recession

3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt

3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation

3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

3.2.5.2. Potential Impact of Inflation on the Market Evolution

+ 4. EXECUTIVE SUMMARY

+ 5. INTRODUCTION

5.1. Overview of Molecular Diagnostics

5.2. Key Technologies Employed in Molecular Diagnostic Solution

5.3. Challenges in the Molecular Diagnostics Domain

5.4. Recent Developments in the Molecular Diagnostics Domain

5.5. Future Perspective in the Molecular Diagnostics Domain

+ 6. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

6.1. Market Drivers

6.2. Market Restraints

6.3. Market Opportunities

6.4. Market Challenges

+ 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET

7.1. Key Assumptions and Methodology

7.2. Global Molecular Diagnostics Market, Till 2035

7.2.1. Scenario Analysis

7.2.1.1. Conservative Scenario

7.2.1.2. Optimistic Scenario

+ 8. MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

8.1. Market Movement Analysis

8.2. Molecular Diagnostics Market: Distribution by Test Type (Current Year and 2035)

8.2.1. Molecular Diagnostics Market for Laboratory Testing, Till 2035

8.2.2. Molecular Diagnostics Market for Point-of-Care Testing, Till 2035

+ 9. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF OFFERING

9.1. Market Movement Analysis

9.2. Molecular Diagnostics Market: Distribution by Type of Offering (Current Year and 2035)

9.2.1. Molecular Diagnostics Market for Instruments, Till 2035

9.2.1.1. Molecular Diagnostics Market for In-house Instruments, Till 2035

9.2.1.2. Molecular Diagnostics Market for Outsourced Instruments, Till 2035

9.2.2. Molecular Diagnostics Marlet for Reagents, till 2035

9.2.3. Molecular Diagnostics Market for Services, till 2035

+ 10. MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

10.1. Market Movement Analysis

10.2. Molecular Diagnostics Market: Distribution by Sample Type (Current Year and 2035)

10.2.1. Molecular Diagnostics Market for Blood, Serum and Plasma, till 2035

10.2.2. Molecular Diagnostics Market for Urine, till 2035

10.2.3. Molecular Diagnostics Market for Other Samples, till 2035

+ 11. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF TECHNOLOGY

11.1. Market Movement Analysis

11.2. Molecular Diagnostics Market: Distribution by Type of Technology (Current Year and 2035)

11.2.1. Molecular Diagnostics Market for PCR, till 2035

11.2.2. Molecular Diagnostics Market for In situ Hybridization, till 2035

11.2.3. Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, till 2035

11.2.4. Molecular Diagnostics Market for Next Generation Sequencing, till 2035

11.2.5. Molecular Diagnostics Market for Microarrays, till 2035

11.2.6. Molecular Diagnostics Market for Mass Spectrometry, till 2035

11.2.7. Molecular Diagnostics Market for Other Technologies, till 2035

+ 12. MOLECULAR DIAGNOSTICS MARKET, BY THERAPEUTIC AREA

12.1. Market Movement Analysis

12.2. Molecular Diagnostics Market: Distribution by Therapeutic Area (Current Year and 2035)

12.2.1. Molecular Diagnostics Market for Infectious Diseases, till 2035

12.2.1.1. Molecular Diagnostics Market for COVID-19, till 2035

12.2.1.2. Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), till 2035

12.2.1.3. Molecular Diagnostics Market for Healthcare-associated Infections, till 2035

12.2.1.4. Molecular Diagnostics Market for Hepatitis, till 2035

12.2.1.5. Molecular Diagnostics Market for HIV, till 2035

12.2.1.6. Molecular Diagnostics Market for Sexually Transmitted Diseases, till 2035

12.2.1.7. Molecular Diagnostics Market for Other Infectious Diseases, till 2035

12.2.2. Molecular Diagnostics Market for Oncological Disorders, till 2035

12.2.2.1. Molecular Diagnostics Market for Lung Cancer, till 2035

12.2.2.2. Molecular Diagnostics Market for Breast Cancer, till 2035

12.2.2.3. Molecular Diagnostics Market for Colorectal Cancer, till 2035

12.2.2.4. Molecular Diagnostics Market for Prostate Cancer, till 2035

12.2.2.5. Molecular Diagnostics Market for Gastric Cancer, till 2035

12.2.2.6. Molecular Diagnostics Market for Other Oncological Disorders, till 2035

12.2.3. Molecular Diagnostics Market for Cardiovascular Diseases, till 2035

12.2.4. Molecular Diagnostics Market for Neurological Diseases, till 2035

12.2.5. Molecular Diagnostics Market for Genetic Diseases, till 2035

12.2.6. Molecular Diagnostics Market for Other Therapeutic Areas, till 2035

+ 13. MOLECULAR DIAGNOSTICS MARKET, BY END USERS

13.1. Market Movement Analysis

13.2. Molecular Diagnostics Market: Distribution by End Users (Current Year and 2035)

13.2.1. Molecular Diagnostics Market for Laboratories, till 2035

13.2.1.1. Molecular Diagnostics Market for Large Laboratories, till 2035

13.2.1.2. Molecular Diagnostics Market for Small and Medium-sized Laboratories, till 2035

13.2.2. Molecular Diagnostics Market for Hospitals, till 2035

13.2.3. Molecular Diagnostics Market for Other End Users, till 2035

+ 14. MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHICAL REGIONS

14.1. Market Movement Analysis

14.2. Molecular Diagnostics Market: Distribution by Geographical Regions (Current Year and 2035)

14.2.1. Molecular Diagnostics Market in North America, till 2035

14.2.1.1. Molecular Diagnostics Market in the US, till 2035

14.2.1.2. Molecular Diagnostics Market in Canada, till 2035

14.2.2. Molecular Diagnostics Market in Europe, till 2035

14.2.2.1. Molecular Diagnostics Market in Austria, till 2035

14.2.2.2. Molecular Diagnostics Market in Belgium, till 2035

14.2.2.3. Molecular Diagnostics Market in France, till 2035

14.2.2.4. Molecular Diagnostics Market in Germany, till 2035

14.2.2.5. Molecular Diagnostics Market in Italy, till 2035

14.2.2.6. Molecular Diagnostics Market in the Netherlands, till 2035

14.2.2.7. Molecular Diagnostics Market in Poland, till 2035

14.2.2.8. Molecular Diagnostics Market in Spain, till 2035

14.2.2.9. Molecular Diagnostics Market in Switzerland, till 2035

14.2.2.10. Molecular Diagnostics Market in the UK, till 2035

14.2.2.11. Molecular Diagnostics Market in Rest of the Europe, till 2035

14.2.3. Molecular Diagnostics Market in Asia, till 2035

14.2.3.1. Molecular Diagnostics Market in China, till 2035

14.2.3.2. Molecular Diagnostics Market in India, till 2035

14.2.3.3. Molecular Diagnostics Market in Indonesia, till 2035

14.2.3.4. Molecular Diagnostics Market in Japan, till 2035

14.2.3.5. Molecular Diagnostics Market in Singapore, till 2035

14.2.3.6. Molecular Diagnostics Market in South Korea, till 2035

14.2.3.7. Molecular Diagnostics Market in Thailand, till 2035

14.2.3.8. Molecular Diagnostics Market in Rest of Asia, till 2035

14.2.4. Molecular Diagnostics Market in Latin America, till 2035

14.2.4.1. Molecular Diagnostics Market in Brazil, till 2035

14.2.4.2. Molecular Diagnostics Market in Argentina, till 2035

14.2.4.3. Molecular Diagnostics Market in Mexico, till 2035

14.2.4.4. Molecular Diagnostics Market in Rest of Latin America, till 2035

14.2.5. Molecular Diagnostics Market in Middle East and North Africa, till 2035

14.2.5.1. Molecular Diagnostics Market in Egypt, till 2035

14.2.5.2. Molecular Diagnostics Market in Israel, till 2035

14.2.5.3. Molecular Diagnostics Market in Saudi Arabia, till 2035

14.2.5.4. Molecular Diagnostics Market in Rest of Middle East and North Africa, till 2035

14.2.6. Molecular Diagnostics Market in Rest of the World, till 2035

14.2.6.1. Molecular Diagnostics Market in Australia, till 2035

14.2.6.2. Molecular Diagnostics Market in New Zealand, till 2035

+ 15. MOLECULAR DIAGNOSTICS MARKET, BY LEADING PLAYERS

15.1. Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenues

+ 16. MARKET OVERVIEW: LEADING MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

16.1. Molecular Diagnostic Solution: Overall Market Landscape

16.1.1. Analysis by Type of Technology

16.1.2. Analysis by Diagnostic Applications

16.1.3. Analysis by Type of Technology and Diagnostic Applications

16.2. Molecular Diagnostics: Solution Providers Landscape

16.2.1. Analysis by Year of Establishment

16.2.2. Analysis by Company Size

16.2.3. Analysis by Location of Headquarters

16.2.4. Analysis by Company Ownership

+ 17. COMPANY COMPETITIVENESS ANALYSIS: MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

17.1. Methodology and Key Parameters Assessed

17.2. Molecular Diagnostic Solution Providers: Competitiveness Analysis of Very Large Players

17.3. Molecular Diagnostic Solution Providers: Competitiveness Analysis of Large Players

17.4. Benchmarking Analysis: Leading Molecular Diagnostics Solution Providers

17.4.1. Benchmarking of Companies

17.4.1.1. Roche: Benchmarking Analysis

17.4.1.2. Abbott: Benchmarking Analysis

17.4.1.3. Thermo Fisher Scientific: Benchmarking Analysis

17.4.1.4. Qiagen: Benchmarking Analysis

17.4.1.5. bioMérieux: Benchmarking Analysis

17.4.1.6. DiaSorin: Benchmarking Analysis

17.4.1.7. Illumina: Benchmarking Analysis

17.4.1.8. Sysmex: Benchmarking Analysis

17.4.1.9. Perkin Elmer: Bnchmarking Analysis

17.4.1.10. Bio-Rad: Benchmarking Analysis

17.4.2. Benchmarking of Parameters

17.4.2.1. Leading Molecular Diagnostics Solution Providers: Benchmarking by Competitiveness

17.4.2.2. Leading Molecular Diagnostic Solution Providers: Benchmarking by Type of Technology Score

17.4.2.3. Leading Molecular Diagnostic Solution Providers: Benchmarking by Diagnostic Applications Score

+ 18. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN NORTH AMERICA

18.1. Detailed Company Profiles

18.1.1. Abbott

18.1.1.1. Company Overview

18.1.1.2. Product Portfolio

18.1.1.3. Financial Information

18.1.1.4. Recent Developments and Future Outlook

18.1.2. Agilent Technologies

18.1.3. BD

18.1.4. Danaher

18.1.5. Thermo Fisher Scientific

18.2. Short Company Profiles

18.2.1. Bio-Rad

18.2.1.1. Company Overview

18.2.1.2. Product Portfolio

18.2.2. Illumina

18.2.3. Hologic

18.2.4. PerkinElmer

18.2.5. QuidelOrtho

+ 19. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN EUROPE

19.1. Detailed Company Profiles

19.1.1. bioMérieux

19.1.1.1. Company Overview

19.1.1.2. Product Portfolio

19.1.1.3. Financial Information

19.1.1.4. Recent Developments and Future Outlook

19.1.2. Grifols

19.1.3. Roche

19.1.4. Siemens Healthineers

19.2. Brief Company Profiles

19.2.1. DiaSorin

19.2.1.1. Company Overview

19.2.1.2. Product Portfolio

19.2.2. Qiagen

+ 20. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN ASIA

20.1. Detailed Company Profiles

20.1.1. Sysmex

20.1.1.1. Company Overview

20.1.1.2. Product Portfolio

20.1.1.3. Financial Information

20.1.1.4. Recent Developments and Future Outlook

20.2. Brief Company Profiles

20.2.1. BGI Genomics

20.2.1.1. Company Overview

20.2.1.2. Product Portfolio

20.2.2. Sansure

20.2.3. Seegene

+ 21. PORTER’S FIVE FORCES ANALYSIS

21.1. Methodology and Assumptions

21.2. Key Parameters

21.2.1. Threats of New Entrants

21.2.2. Bargaining Power of Buyers

21.2.3. Bargaining Power of Suppliers

21.2.4. Threats of Substitute Products

21.2.5. Rivalry among Existing Competitors

21.3. Porter’s Five Force Analysis:Harvey Ball Analysis

21.4. Concluding Remarks

+ 22. APPENDIX I: TABULATED DATA

+ 23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Research Assumptions

Figure 2.2 Research Methodology: Project Methodology

Figure 2.3 Research Methodology: Forecast Methodology

Figure 2.4 Research Methodology: Robust Quality Control

Figure 2.5 Research Methodology: Key Market Segmentations

Figure 5.1 Key Technologies Employed in Molecular Diagnostic Solution

Figure 5.2 Challenges in the Molecular Diagnostics Domain

Figure 6.1 Market Drivers

Figure 6.2 Market Restraints

Figure 6.3 Market Opportunities

Figure 6.4 Market Challenges

Figure 7.1 Global Molecular Diagnostics Market, Till 2035 (USD Billion)

Figure 7.2 Global Molecular Diagnostics Market, Conservative Scenario, till 2035 (USD Billion)

Figure 7.3 Global Molecular Diagnostics Market, Optimistic Scenario, till 2035 (USD Billion)

Figure 8.1 Molecular Diagnostics Market: Distribution by Test Type, Current Year and 2035

Figure 8.2 Molecular Diagnostics Market for Laboratory Testing, Till 2035 (USD Billion)

Figure 8.3 Molecular Diagnostics Market for Point-of-Care Testing, Till 2035 (USD Billion)

Figure 9.1 Molecular Diagnostics Market: Distribution by Type of Offering, Current Year and 2035

Figure 9.2 Molecular Diagnostics Market for Instruments, Till 2035 (USD Billion)

Figure 9.3 Molecular Diagnostics Market for In-house Instruments, Till 2035 (USD Billion)

Figure 9.4 Molecular Diagnostics Market for Outsourced Instruments, Till 2035 (USD Billion)

Figure 9.5 Molecular Diagnostics Market for Reagents, Till 2035 (USD Billion)

Figure 9.6 Molecular Diagnostics Market for Services, Till 2035 (USD Billion)

Figure 10.1 Molecular Diagnostics Market: Distribution by Sample Type, Current Year and 2035

Figure 10.2 Molecular Diagnostics Market for Blood, Serum and Plasma, Till 2035 (USD Billion)

Figure 10.3 Molecular Diagnostics Market for Urine, Till 2035 (USD Billion)

Figure 10.4 Molecular Diagnostics Market for Others, Till 2035 (USD Billion)

Figure 11.1 Molecular Diagnostics Market: Distribution by Type of Technology, Current Year and 2035

Figure 11.2 Molecular Diagnostics Market for PCR, Till 2035 (USD Billion)

Figure 11.3 Molecular Diagnostics Market for In Situ Hybridization, Till 2035 (USD Billion)

Figure 11.4 Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, Till 2035 (USD Billion)

Figure 11.5 Molecular Diagnostics Market for Next Generation Sequencing, Till 2035 (USD Billion)

Figure 11.6 Molecular Diagnostics Market for Microarrays, Till 2035 (USD Billion)

Figure 11.7 Molecular Diagnostics Market for Mass Spectrometry, Till 2035 (USD Billion)

Figure 11.8 Molecular Diagnostics Market for Other Technologies, Till 2035 (USD Billion)

Figure 12.1 Molecular Diagnostics Market: Distribution by Therapeutic Area, Current Year and 2035

Figure 12.2 Molecular Diagnostics Market for Infectious Diseases, Till 2035 (USD Billion)

Figure 12.3 Molecular Diagnostics Market for COVID-19, Till 2035 (USD Billion)

Figure 12.4 Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), Till 2035 (USD Billion)

Figure 12.5 Molecular Diagnostics Market for Healthcare-associated Infections, Till 2035 (USD Billion)

Figure 12.6 Molecular Diagnostics Market for Hepatitis, Till 2035 (USD Billion)

Figure 12.7 Molecular Diagnostics Market for HIV, Till 2035 (USD Billion)

Figure 12.8 Molecular Diagnostics Market for Sexually Transmitted Diseases, Till 2035 (USD Billion)

Figure 12.9 Molecular Diagnostics Market for Other Infectious Diseases, Till 2035 (USD Billion)

Figure 12.10 Molecular Diagnostics Market for Oncological Disorders, Till 2035 (USD Billion)

Figure 12.11 Molecular Diagnostics Market for Lung Cancer, Till 2035 (USD Billion)

Figure 12.12 Molecular Diagnostics Market for Breast Cancer, Till 2035 (USD Billion)

Figure 12.13 Molecular Diagnostics Market for Colorectal Cancer, Till 2035 (USD Billion)

Figure 12.14 Molecular Diagnostics Market for Prostate Cancer, Till 2035 (USD Billion)

Figure 12.15 Molecular Diagnostics Market for Gastric Cancer, Till 2035 (USD Billion)

Figure 12.16 Molecular Diagnostics Market for Other Oncological Disorders, Till 2035 (USD Billion)

Figure 12.17 Molecular Diagnostics Market for Cardiovascular Diseases, Till 2035 (USD Billion)

Figure 12.18 Molecular Diagnostics Market for Neurological Diseases, Till 2035 (USD Billion)

Figure 12.19 Molecular Diagnostics Market for Genetic Diseases, Till 2035 (USD Billion)

Figure 12.20 Molecular Diagnostics Market for Other Therapeutic Areas, Till 2035 (USD Billion)

Figure 13.1 Molecular Diagnostics Market: Distribution by End Users, Current Year and 2035

Figure 13.2 Molecular Diagnostics Market for Laboratories, Till 2035 (USD Billion)

Figure 13.3 Molecular Diagnostics Market for Large Laboratories, Till 2035 (USD Billion)

Figure 13.4 Molecular Diagnostics Market for Small and Medium-sized Laboratories, Till 2035 (USD Billion)

Figure 13.5 Molecular Diagnostics Market for Hospitals, Till 2035 (USD Billion)

Figure 13.6 Molecular Diagnostics Market for Other End Users, Till 2035 (USD Billion)

Figure 14.1 Molecular Diagnostics Market: Distribution by Geographical Regions, Current Year and 2035

Figure 14.2 Molecular Diagnostics Market in North America, Till 2035 (USD Billion)

Figure 14.3 Molecular Diagnostics Market in the US, Till 2035 (USD Billion)

Figure 14.4 Molecular Diagnostics Market in Canada, Till 2035 (USD Billion)

Figure 14.5 Molecular Diagnostics Market in Europe, Till 2035 (USD Billion)

Figure 14.6 Molecular Diagnostics Market in Austria, Till 2035 (USD Billion)

Figure 14.7 Molecular Diagnostics Market in Belgium, Till 2035 (USD Billion)

Figure 14.8 Molecular Diagnostics Market in France, Till 2035 (USD Billion)

Figure 14.9 Molecular Diagnostics Market in Germany, Till 2035 (USD Billion)

Figure 14.10 Molecular Diagnostics Market in Italy, Till 2035 (USD Billion)

Figure 14.11 Molecular Diagnostics Market in the Netherlands, Till 2035 (USD Billion)

Figure 14.12 Molecular Diagnostics Market in Poland, Till 2035 (USD Billion)

Figure 14.13 Molecular Diagnostics Market in Spain, Till 2035 (USD Billion)

Figure 14.14 Molecular Diagnostics Market in Switzerland, Till 2035 (USD Billion)

Figure 14.15 Molecular Diagnostics Market in the UK, Till 2035 (USD Billion)

Figure 14.16 Molecular Diagnostics Market in Rest of the Europe, Till 2035 (USD Billion)

Figure 14.17 Molecular Diagnostics Market in Asia, Till 2035 (USD Billion)

Figure 14.18 Molecular Diagnostics Market in China, Till 2035 (USD Billion)

Figure 14.19 Molecular Diagnostics Market in India, Till 2035 (USD Billion)

Figure 14.20 Molecular Diagnostics Market in Indonesia, Till 2035 (USD Billion)

Figure 14.21 Molecular Diagnostics Market in Japan, Till 2035 (USD Billion)

Figure 14.22 Molecular Diagnostics Market in Singapore, Till 2035 (USD Billion)

Figure 14.23 Molecular Diagnostics Market in South Korea, Till 2035 (USD Billion)

Figure 14.24 Molecular Diagnostics Market in Thailand, Till 2035 (USD Billion)

Figure 14.25 Molecular Diagnostics Market in Rest of the Asia, Till 2035 (USD Billion)

Figure 14.26 Molecular Diagnostics Market in Latin America, Till 2035 (USD Billion)

Figure 14.27 Molecular Diagnostics Market in Brazil, Till 2035 (USD Billion)

Figure 14.28 Molecular Diagnostics Market in Argentina, Till 2035 (USD Billion)

Figure 14.29 Molecular Diagnostics Market in Mexico, Till 2035 (USD Billion)

Figure 14.30 Molecular Diagnostics Market in Rest of Latin America, Till 2035 (USD Billion)

Figure 14.31 Molecular Diagnostics Market in Middle East and North Africa, Till 2035 (USD Billion)

Figure 14.32 Molecular Diagnostics Market in Egypt, Till 2035 (USD Billion)

Figure 14.33 Molecular Diagnostics Market in Israel, Till 2035 (USD Billion)

Figure 14.34 Molecular Diagnostics Market in Saudi Arabia, Till 2035 (USD Billion)

Figure 14.35 Molecular Diagnostics Market in Rest of Middle East and North Africa, Till 2035 (USD Billion)

Figure 14.36 Molecular Diagnostics Market in Rest of the World, Till 2035 (USD Billion)

Figure 14.37 Molecular Diagnostics Market in Australia, Till 2035 (USD Billion)

Figure 14.38 Molecular Diagnostics Market in New Zealand, Till 2035 (USD Billion)

Figure 15.1 Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenue (FY23, USD Billion)

Figure 16.1 Molecular Diagnostic Solution: Distribution by Type of Technology

Figure 16.2 Molecular Diagnostic Solution: Distribution by Diagnostic Applications

Figure 16.3 Molecular Diagnostic Solution: Distribution by Type of Technology and Diagnostic Applications

Figure 16.4 Molecular Diagnostics Solution Providers: Distribution by Year of Establishment

Figure 16.5 Molecular Diagnostics Solution Providers: Distribution by Company Size

Figure 16.6 Molecular Diagnostics Solution Providers: Distribution by Location of Headquarters

Figure 16.7 Molecular Diagnostics Solution Providers: Distribution by Company Ownership

Figure 17.1 Molecular Diagnostic Solution Providers: Competitiveness Analysis of Very Large Players

Figure 17.2 Molecular Diagnostic Solution Providers: Competitiveness Analysis of Large Players

Figure 17.3 Roche: Benchmarking Analysis

Figure 17.4 Abbott: Benchmarking Analysis

Figure 17.5 Thermo Fisher Scientific: Benchmarking Analysis

Figure 17.6 Qiagen: Benchmarking Analysis

Figure 17.7 bioMérieux: Benchmarking Analysis

Figure 17.8 DiaSorin: Benchmarking Analysis

Figure 17.9 Illumina: Benchmarking Analysis

Figure 17.10 Sysmex: Benchmarking Analysis

Figure 17.11 Perkin Elmer: Benchmarking Analysis

Figure 17.12 Bio-Rad: Benchmarking Analysis

Figure 17.13 Leading Molecular Diagnostic Solution Providers: Benchmarking by Competitiveness

Figure 17.14 Leading Molecular Diagnostic Solution Providers: Benchmarking by Type of Technology Score

Figure 17.15 Leading Molecular Diagnostic Solution Providers: Benchmarking by Diagnostic Applications Score

Figure 18.1 Abbott: Financial Information (USD Billion)

Figure 18.2 Agilent Technologies: Financial Information (USD Billion)

Figure 18.3 BD: Financial Information (USD Billion)

Figure 18.4 Danaher: Financial Information (USD Billion)

Figure 18.5 Thermo Fisher Scientific: Financial Information (CHF Billion)

Figure 19.1 bioMérieux: Financial Information (EUR Billion)

Figure 19.2 Grifols: Financial Information (EUR Billion)

Figure 19.3 Roche: Financial Information (CHF Billion)

Figure 19.4 Siemens Healthineers: Financial Information (EUR Billion)

Figure 20.1 Sysmex: Financial Information (JPY Billion)

Figure 21.1 Threats of New Entrants

Figure 21.2 Bargaining Power of Buyers

Figure 21.3 Bargaining Power of Suppliers

Figure 21.4 Threats of Substitute Products

Figure 21.5 Rivalry among Existing Competitors

Figure 21.6 Porter’s Five Force Analysis: Harvey Ball Analysis

+ List of Tables

Table 16.1 Leading Molecular Diagnostics Solution Providers: Information on Year of Establishment, Headquarters, Company Ownership, Type of Technology and Diagnostic Applications

Table 16.2 Other Leading Molecular Diagnostics Solution Providers: Information on Year of Establishment, Headquarters and Company Ownership

Table 18.1 Abbott: Company Overview

Table 18.2 Abbott: Product Portfolio

Table 18.3 Abbott: Recent Developments and Future Outlook

Table 18.4 Agilent Technologies: Company Overview

Table 18.5 Agilent Technologies: Product Portfolio

Table 18.6 Agilent Technologies: Recent Developments and Future Outlook

Table 18.7 BD: Company Overview

Table 18.8 BD: Product Portfolio

Table 18.9 BD: Recent Developments and Future Outlook

Table 18.10 Danaher: Company Overview

Table 18.11 Danaher: Product Portfolio

Table 18.12 Danaher: Recent Developments and Future Outlook

Table 18.13 Roche: Company Overview

Table 18.14 Roche: Product Portfolio

Table 18.15 Roche: Recent Developments and Future Outlook

Table 18.16 Thermo Fisher Scientific: Company Overview

Table 18.17 Thermo Fisher Scientific: Product Portfolio

Table 18.18 Thermo Fisher Scientific: Recent Developments and Future Outlook

Table 18.19 Bio-Rad: Company Overview

Table 18.20 Bio-Rad: Product Portfolio

Table 18.21 Illumina: Company Overview

Table 18.22 Illumina: Product Portfolio

Table 18.23 Hologic: Company Overview

Table 18.24 Hologic: Product Portfolio

Table 18.25 PerkinElmer: Company Overview

Table 18.26 PerkinElmer: Product Portfolio

Table 18.27 QuidelOrtho: Company Overview

Table 18.28 QuidelOrtho: Product Portfolio

Table 19.1 bioMérieux: Company Overview

Table 19.2 bioMérieux: Product Portfolio

Table 19.3 bioMérieux: Recent Developments and Future Outlook

Table 19.4 Grifols: Company Overview

Table 19.5 Grifols: Product Portfolio

Table 19.6 Grifols: Recent Developments and Future Outlook

Table 19.7 Siemens Healthineers: Company Overview

Table 19.8 Siemens Healthineers: Product Portfolio

Table 19.9 Siemens Healthineers: Recent Developments and Future Outlook

Table 19.10 DiaSorin: Company Overview

Table 19.11 DiaSorin: Product Portfolio

Table 19.12 Qiagen: Company Overview

Table 19.13 Qiagen: Product Portfolio

Table 20.1 Sysmex: Company Overview

Table 20.2 Sysmex: Product Portfolio

Table 20.3 Sysmex: Recent Developments and Future Outlook

Table 20.4 BGI Genomics: Company Overview

Table 20.5 BGI Genomics: Product Portfolio

Table 20.6 Sansure: Company Overview

Table 20.7 Sansure: Product Portfolio

Table 20.8 Seegene: Company Overview

Table 20.9 Seegene: Product Portfolio

Table 22.1 Global Molecular Diagnostics Market, Till 2035 (USD Billion)

Table 22.2 Global Molecular Diagnostics Market, Conservative Scenario, till 2035 (USD Billion)

Table 22.3 Global Molecular Diagnostics Market, Optimistic Scenario, till 2035 (USD Billion)

Table 22.4 Molecular Diagnostics Market: Distribution by Test Type, Current Year and 2035

Table 22.5 Molecular Diagnostics Market for Laboratory Testing, Till 2035 (USD Billion)

Table 22.6 Molecular Diagnostics Market for Point-of-Care Testing, Till 2035 (USD Billion)

Table 22.7 Molecular Diagnostics Market: Distribution by Type of Offering, Current Year and 2035

Table 22.8 Molecular Diagnostics Market for Instruments, Till 2035 (USD Billion)

Table 22.9 Molecular Diagnostics Market for In-house Instruments, Till 2035 (USD Billion)

Table 22.10 Molecular Diagnostics Market for Outsourced Instruments, Till 2035 (USD Billion)

Table 22.11 Molecular Diagnostics Market for Reagents, Till 2035 (USD Billion)

Table 22.12 Molecular Diagnostics Market for Services, Till 2035 (USD Billion)

Table 22.13 Molecular Diagnostics Market: Distribution by Sample Type, Current Year and 2035

Table 22.14 Molecular Diagnostics Market for Blood, Serum and Plasma, Till 2035 (USD Billion)

Table 22.15 Molecular Diagnostics Market for Urine, Till 2035 (USD Billion)

Table 22.16 Molecular Diagnostics Market for Others, Till 2035 (USD Billion)

Table 22.17 Molecular Diagnostics Market: Distribution by Type of Technology, Current Year and 2035

Table 22.18 Molecular Diagnostics Market for PCR, Till 2035 (USD Billion)

Table 22.19 Molecular Diagnostics Market for In situ Hybridization, Till 2035 (USD Billion)

Table 22.20 Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, Till 2035 (USD Billion)

Table 22.21 Molecular Diagnostics Market for Next Generation Sequencing, Till 2035 (USD Billion)

Table 22.22 Molecular Diagnostics Market for Microarrays, Till 2035 (USD Billion)

Table 22.23 Molecular Diagnostics Market for Mass Spectrometry, Till 2035 (USD Billion)

Table 22.24 Molecular Diagnostics Market for Other Technologies, Till 2035 (USD Billion)

Table 22.25 Molecular Diagnostics Market: Distribution by Therapeutic Area, Current Year and 2035

Table 22.26 Molecular Diagnostics Market for Infectious Diseases, Till 2035 (USD Billion)

Table 22.27 Molecular Diagnostics Market for COVID-19, Till 2035 (USD Billion)

Table 22.28 Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), Till 2035 (USD Billion)

Table 22.29 Molecular Diagnostics Market for Healthcare-associated Infections, Till 2035 (USD Billion)

Table 22.30 Molecular Diagnostics Market for Hepatitis, Till 2035 (USD Billion)

Table 22.31 Molecular Diagnostics Market for HIV, Till 2035 (USD Billion)

Table 22.32 Molecular Diagnostics Market for Sexually Transmitted Diseases, Till 2035 (USD Billion)

Table 22.33 Molecular Diagnostics Market for Other Infectious Diseases, Till 2035 (USD Billion)

Table 22.34 Molecular Diagnostics Market for Oncological Disorders, Till 2035 (USD Billion)

Table 22.35 Molecular Diagnostics Market for Lung Cancer, Till 2035 (USD Billion)

Table 22.36 Molecular Diagnostics Market for Breast Cancer, Till 2035 (USD Billion)

Table 22.37 Molecular Diagnostics Market for Colorectal Cancer, Till 2035 (USD Billion)

Table 22.38 Molecular Diagnostics Market for Prostate Cancer, Till 2035 (USD Billion)

Table 22.39 Molecular Diagnostics Market for Gastric Cancer, Till 2035 (USD Billion)

Table 22.40 Molecular Diagnostics Market for Other Oncological Disorders, Till 2035 (USD Billion)

Table 22.41 Molecular Diagnostics Market for Cardiovascular Diseases, Till 2035 (USD Billion)

Table 22.42 Molecular Diagnostics Market for Neurological Diseases, Till 2035 (USD Billion)

Table 22.43 Molecular Diagnostics Market for Genetic Diseases, Till 2035 (USD Billion)

Table 22.44 Molecular Diagnostics Market for Other Therapeutic Areas, Till 2035 (USD Billion)

Table 22.45 Molecular Diagnostics Market: Distribution by End Users, Current Year and 2035

Table 22.46 Molecular Diagnostics Market for Laboratories, Till 2035 (USD Billion)

Table 22.47 Molecular Diagnostics Market for Large Laboratories, Till 2035 (USD Billion)

Table 22.48 Molecular Diagnostics Market for Small and Medium-sized Laboratories, Till 2035 (USD Billion)

Table 22.49 Molecular Diagnostics Market for Hospitals, Till 2035 (USD Billion)

Table 22.50 Molecular Diagnostics Market for Other End Users, Till 2035 (USD Billion)

Table 22.51 Molecular Diagnostics Market: Distribution by Geographical Regions, Current Year and 2035

Table 22.52 Molecular Diagnostics Market in North America, Till 2035 (USD Billion)

Table 22.53 Molecular Diagnostics Market in the US, Till 2035 (USD Billion)

Table 22.54 Molecular Diagnostics Market in Canada, Till 2035 (USD Billion)

Table 22.55 Molecular Diagnostics Market in Europe, Till 2035 (USD Billion)

Table 22.56 Molecular Diagnostics Market in Austria, Till 2035 (USD Billion)

Table 22.57 Molecular Diagnostics Market in Belgium, Till 2035 (USD Billion)

Table 22.58 Molecular Diagnostics Market in France, Till 2035 (USD Billion)

Table 22.59 Molecular Diagnostics Market in Germany, Till 2035 (USD Billion)

Table 22.60 Molecular Diagnostics Market in Italy, Till 2035 (USD Billion)

Table 22.61 Molecular Diagnostics Market in the Netherlands, Till 2035 (USD Billion)

Table 22.62 Molecular Diagnostics Market in Poland, Till 2035 (USD Billion)

Table 22.63 Molecular Diagnostics Market in Spain, Till 2035 (USD Billion)

Table 22.64 Molecular Diagnostics Market in Switzerland, Till 2035 (USD Billion)

Table 22.65 Molecular Diagnostics Market in the UK, Till 2035 (USD Billion)

Table 22.66 Molecular Diagnostics Market in Rest of the Europe, Till 2035 (USD Billion)

Table 22.67 Molecular Diagnostics Market in Asia, Till 2035 (USD Billion)

Table 22.68 Molecular Diagnostics Market in China, Till 2035 (USD Billion)

Table 22.69 Molecular Diagnostics Market in India, Till 2035 (USD Billion)

Table 22.70 Molecular Diagnostics Market in Indonesia, Till 2035 (USD Billion)

Table 22.71 Molecular Diagnostics Market in Japan, Till 2035 (USD Billion)

Table 22.72 Molecular Diagnostics Market in Singapore, Till 2035 (USD Billion)

Table 22.73 Molecular Diagnostics Market in South Korea, Till 2035 (USD Billion)

Table 22.74 Molecular Diagnostics Market in Thailand, Till 2035 (USD Billion)

Table 22.75 Molecular Diagnostics Market in Rest of the Asia, Till 2035 (USD Billion)

Table 22.76 Molecular Diagnostics Market in Latin America, Till 2035 (USD Billion)

Table 22.77 Molecular Diagnostics Market in Brazil, Till 2035 (USD Billion)

Table 22.78 Molecular Diagnostics Market in Argentina, Till 2035 (USD Billion)

Table 22.79 Molecular Diagnostics Market in Mexico, Till 2035 (USD Billion)

Table 22.80 Molecular Diagnostics Market in Rest of Latin America, Till 2035 (USD Billion)

Table 22.81 Molecular Diagnostics Market in Middle East and North Africa, Till 2035 (USD Billion)

Table 22.82 Molecular Diagnostics Market in Egypt, Till 2035 (USD Billion)

Table 22.83 Molecular Diagnostics Market in Israel, Till 2035 (USD Billion)

Table 22.84 Molecular Diagnostics Market in Saudi Arabia, Till 2035 (USD Billion)

Table 22.85 Molecular Diagnostics Market in Rest of Middle East and North Africa, Till 2035 (USD Billion)

Table 22.86 Molecular Diagnostics Market in Rest of the World, Till 2035 (USD Billion)

Table 22.87 Molecular Diagnostics Market in Australia, Till 2035 (USD Billion)

Table 22.88 Molecular Diagnostics Market in New Zealand, Till 2035 (USD Billion)

Table 22.89 Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenues (FY23, USD Billion

Table 22.90 Molecular Diagnostic Solution: Distribution by Type of Technology

Table 22.91 Molecular Diagnostic Solution: Distribution by Diagnostic Applications

Table 22.92 Molecular Diagnostic Solution: Distribution by Type of Technology and Diagnostic Applications

Table 22.93 Molecular Diagnostics Solution Providers: Distribution by Year of Establishment

Table 22.94 Molecular Diagnostics Solution Providers: Distribution by Company Size

Table 22.95 Molecular Diagnostics Solution Providers: Distribution by Location of Headquarters

Table 22.96 Molecular Diagnostics Solution Providers: Distribution by Company Ownership

Table 22.97 Abbott: Financial Information (USD Billion)

Table 22.98 Agilent Technologies: Financial Information (USD Billion)

Table 22.99 BD: Financial Information (USD Billion)

Table 22.100 Danaher: Financial Information (USD Billion)

Table 22.101 Thermo Fisher Scientific: Financial Information (CHF Billion)

Table 22.102 bioMérieux: Financial Information (EUR Billion)

Table 22.103 Grifols: Financial Information (EUR Billion)

Table 22.104 Roche: Financial Information (CHF Billion)

Table 22.105 Siemens Healthineers: Financial Information (EUR Billion)

Table 22.106 Sysmex: Financial Information (JPY Billion)

+ List of Companies and Organizations

Please reach out to our team for more details.

Molecular Diagnostics Market

Market Size

Market Report: Key Takeaways

Market Size & Trends

Key Market Statistics

Market Overview

Recent Developments in Molecular Diagnostics Market

Molecular Diagnostics Market Trends

Market Share by Type of Sample: Blood, Serum and Plasma Segment to Hold the Highest Market Share

Market Share by Test Type: Laboratory Testing Segment Holds the Largest Market Share

Market Share by Type of Offering: Reagents Segment to Dominate the Overall Market

Market Share by Type of Technology: Next Generation Sequencing Segment to Grow at a Higher CAGR

Market Share by Therapeutic Area: Infectious Diseases Segment to Dominate the Overall Market

Market Share by End User: Laboratories Segment to Grow at a Higher CAGR

Key Market Insights

Molecular Diagnostics Companies Competitive Landscape

Market Size Analysis: Global Market to Grow at High CAGR

Regional Analysis: Which Region Holds the Largest Molecular Diagnostics Market Share?

North America is Leading the Market

Asia-Pacific: An Emerging Growth Spot

Market Drivers: Growing Shift Towards Personalized Healthcare and Increasing Prevalence of Chronic Diseases

Market Challenges: Data Security Concerns May Hinder the Growth

Market Segmentation Insights

Table of Content

The Future of Autonomous Deliveries: Integrating Drones and Self-Driving Vehicles

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment

Molecular Diagnostics Market

Market Size

Market Report: Key Takeaways

Market Size & Trends

Key Market Statistics

Market Overview

Recent Developments in Molecular Diagnostics Market

Molecular Diagnostics Market Trends

Market Share Insights

Market Share by Type of Sample: Blood, Serum and Plasma Segment to Hold the Highest Market Share

Market Share by Test Type: Laboratory Testing Segment Holds the Largest Market Share

Market Share by Type of Offering: Reagents Segment to Dominate the Overall Market

Market Share by Type of Technology: Next Generation Sequencing Segment to Grow at a Higher CAGR

Market Share by Therapeutic Area: Infectious Diseases Segment to Dominate the Overall Market

Market Share by End User: Laboratories Segment to Grow at a Higher CAGR

Key Market Insights

Molecular Diagnostics Companies Competitive Landscape

Market Size Analysis: Global Market to Grow at High CAGR

Regional Analysis: Which Region Holds the Largest Molecular Diagnostics Market Share?

North America is Leading the Market

Asia-Pacific: An Emerging Growth Spot

Market Drivers: Growing Shift Towards Personalized Healthcare and Increasing Prevalence of Chronic Diseases

Market Challenges: Data Security Concerns May Hinder the Growth

Market Segmentation Insights

Table of Content

The Future of Autonomous Deliveries: Integrating Drones and Self-Driving Vehicles

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment